Zeng and colleagues designed a new series of pyrimidine-amino-pyridine by modifying the similar structures containing the piperidine-amino-pyrimidine; among the new series St.13 (Table 3) showed promising results against different cancer cell lines and CDK2, in comparison with the Palbociclib positive control. This evidence concerns the gene CDK2 and cancer.